Get the Daily Brief
Latest Biotech News
Breakthrough Electrospinning Creates Biodegradable and Edible Fibers from Milk and Plant Proteins
Penn State researchers pioneered an electrospinning technique combining casein milk proteins with plant-derived cellulose (HPMC) to fabricate ultra-fine nanofibers potentially usable in...
Innovative AI Hardware Accelerator Speeds 6G Wireless Signal Processing
MIT researchers unveiled a photonic chip designed to perform AI computations for wireless signal classification at nanosecond timescales. This hardware accelerator offers approximately 100 times...
Alamar Biosciences and Partners Launch Major Proteomics Initiative in Alzheimer's Research
Alamar Biosciences, in collaboration with the Alzheimer's Disease Data Initiative and Gates Ventures, launched a large-scale plasma proteomic profiling project targeting Alzheimer's disease and...
Recursion Biotech Cuts 20% Workforce Amid Funding and Pipeline Challenges
Salt Lake City-based AI-driven drug discovery company Recursion announced a 20% workforce reduction, reflecting pipeline pruning and a challenging capital environment. The restructuring aims to...
Eli Lilly and Juvena Strike $650M Deal to Advance Muscle Health Therapies
Eli Lilly has entered into a strategic partnership with Juvena Therapeutics, committing over $650 million in milestones to develop novel muscle-boosting drugs. Juvena's AI-driven platform will...
Merck Gains FDA Nod for Pediatric RSV Antibody as Vaccine Advisory Faces Uncertainty
Merck & Co. secured FDA approval for Enflonsia (cesrovimab), a long-acting monoclonal antibody to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants....
FDA Approves Nuvation’s Ibtrozi for Advanced Lung Cancer
The U.S. Food and Drug Administration has granted approval to Nuvation Bio for Ibtrozi (taletrectinib), an oral medication targeting advanced ROS1-positive non-small cell lung cancer (NSCLC)....
Recursion cuts 20% of workforce amid pipeline cuts
Recursion Pharmaceuticals announced a workforce reduction of approximately 20% following strategic cuts to its drug development pipeline amidst challenging capital markets. The downsizing reflects...
SpliceBio lands $135M to fund novel gene therapy
SpliceBio secured $135 million in Series B financing from major pharma venture arms, propelling clinical development of a pioneering dual AAV gene therapy for Stargardt disease. This substantial...
Merck RSV drug approved – CDC committee in flux
Merck's monoclonal antibody Enflonsia gains FDA approval for preventing RSV in infants, entering a competitive market alongside Sanofi and AstraZeneca's product. This regulatory milestone...
Biomanufacturing growth contrasts with lab space market fluctuations
The U.S. life sciences sector experiences dichotomous trends with burgeoning biomanufacturing investments exceeding $270 billion fueling domestic expansion, driven by reshoring and supply chain...
Innovations in diagnostic technologies and therapeutic platforms
Emerging diagnostic tools harness AI, nanotechnology, and advanced materials to improve disease detection and patient care. Technologies include an AI-powered nanopore viral detection platform...
Regulatory shifts and challenges impact biotech and healthcare sectors
Policy decisions and administrative actions are significantly affecting the biotech and healthcare environment. NIH staff protests oppose drastic budget cuts and grant cancellations, citing...
Biotech funding and strategic collaborations highlight industry growth
Significant capital inflows and partnerships shape the biotech landscape. SpliceBio secured $135 million in a Series B round to advance gene therapy for Stargardt disease, engaging top strategic...
Cancer research innovations identify metabolic and molecular targets
Groundbreaking studies reveal novel molecular mechanisms and metabolic vulnerabilities in cancer. Discoveries include new enzyme families degrading bacterial carbohydrates, emerging tumor energy...
Gene editing and molecular biology breakthroughs enhance therapeutic potential
Recent advances include enhancement of CRISPR-Cas9 gene editing precision by inducing autophagy to shift DNA repair toward homologous recombination, increasing accuracy of genome modifications....
Precision oncology advances: CAR-T therapies targeting novel antigens and therapy resistance
Cutting-edge cancer therapeutics include innovative CAR-T cell designs targeting solid tumors through molecular targets like Eva1, enhancing immune synapse formation and cytotoxicity....
Recursion Pharmaceuticals reduces workforce amid funding challenges
Recursion Pharmaceuticals, an AI-driven biopharmaceutical company, announced layoffs affecting 20% of its staff as part of organizational streamlining and pipeline pruning. This step follows...
AI and machine learning accelerate biotech discovery and target identification
Artificial intelligence is reshaping life sciences by enabling faster hypothesis generation, target discovery, and biomarker identification. Leading firms and scientific teams deploy advanced AI...
FDA approval shakes up pediatric RSV treatment amid CDC upheaval
Merck has gained FDA approval for Enflonsia (clesrovimab), a monoclonal antibody for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants. This entry intensifies...